Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Nov
12
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo